HopeStage
Back to all studies
CompletedNCT04846881

Iclepertin for cognition and daily function in schizophrenia: CONNEX-2

About this titleRead the official source — NCT04846881

Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Medication studyAges 18–50Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
Bellflower and 126 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 24, 2021
Recruitment status
Completed
Enrollment listed in the registry
611
Sponsor
Boehringer Ingelheim
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, France, Argentina, ...
Age range
From 18 Years to 50 Years
Official registry ID
NCT04846881
Official title
Show the full official title

A Phase III Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-2)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bellflower, United States · Costa Mesa, United States · Long Beach, United States

112 more locations
  • Los Angeles, United States
  • Orange, United States
  • Torrance, United States
  • New Haven, United States
  • Hialeah, United States
  • Miami, United States
  • West Palm Beach, United States
  • Chicago, United States
  • Baltimore, United States
  • St Louis, United States
  • Cedarhurst, United States
  • New York, United States
  • Independence, United States
  • Dallas, United States
  • Fort Worth, United States
  • Salem, United States
  • Bellevue, United States
  • CABA, Argentina
  • Córdoba, Argentina
  • La Plata, Argentina
  • Mendoza, Argentina
  • Rosario, Argentina
  • Rio de Janeiro, Brazil
  • São Bernardo do Campo, Brazil
  • São Paulo, Brazil
  • Santiago, Chile
  • Segunda Región, Chile
  • Rijeka, Croatia
  • Zagreb, Croatia
  • Bordeaux, France
  • Clermont-Ferrand, France
  • Créteil, France
  • Le Chesnay-Rocquencourt, France
  • Lille, France
  • Montpellier, France
  • Nantes, France
  • Nice, France
  • Nîmes, France
  • Rennes, France
  • Rouffach, France
  • Saint-Priest-en-Jarez, France
  • Budapest, Hungary
  • Debrecen, Hungary
  • Pécs, Hungary
  • Aichi, Toyoake, Japan
  • Aichi, Toyota, Japan
  • Chiba, Chiba, Japan
  • Fukuoka, Chikugo, Japan
  • Fukuoka, Fukuoka, Japan
  • Fukuoka, Kurume, Japan
  • Gumma, Kiryu, Japan
  • Hokkaido, Sapporo, Japan
  • Hyogo, Kobe, Japan
  • Ishikwa, Kahoku-gun, Japan
  • Kanagawa, Kawasaki, Japan
  • Kanagawa, Yokohama, Japan
  • Kumamoto, Kumamoto, Japan
  • Kumamoto, Yatsushiro, Japan
  • Nagano, Suwa, Japan
  • Nara, Kashihara, Japan
  • Okinawa, Ginowan, Japan
  • Osaka, Osaka, Japan
  • Saga, Karatsu, Japan
  • Saga, Tosu, Japan
  • Tokyo, Adachi-ku, Japan
  • Tokyo, Bunkyo-ku, Japan
  • Tokyo, Kita-ku, Japan
  • Tokyo, Minato-ku, Japan
  • Tokyo, Ota-ku, Japan
  • Tokyo, Shibuya-ku, Japan
  • Tokyo, Shinjuku-ku, Japan
  • Toyama, Nanto, Japan
  • Ipoh, Malaysia
  • Kuala Lumpur, Malaysia
  • Kuching, Malaysia
  • Seremban, Negeri Sembilan, Malaysia
  • Groningen, Netherlands
  • Maastricht, Netherlands
  • Bełchatów, Poland
  • Bialystok, Poland
  • Gdansk, Poland
  • Gliwice, Poland
  • Gmina Świecie, Poland
  • Szczecin, Poland
  • Zabrze, Poland
  • Bucharest, Romania
  • Sibiu, Romania
  • Belgrade, Serbia
  • Novi Kneževac, Serbia
  • Novi Sad, Serbia
  • Singapore, Singapore
  • Bojnice, Slovakia
  • Košice, Slovakia
  • Rimavská Sobota, Slovakia
  • Busan, South Korea
  • Daegu, South Korea
  • Incheon, South Korea
  • Jeonju, South Korea
  • Seoul, South Korea
  • Barcelona, Spain
  • Collado de Villalba, Spain
  • Córdoba, Spain
  • Getafe, Spain
  • Majadahonda, Spain
  • Palma, Spain
  • Salamanca, Spain
  • Sant Boi de Llobregat, Spain
  • Seville, Spain
  • Valencia, Spain
  • Vigo, Spain
  • Zamora, Spain
  • Nove, Ukraine

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Iclepertin and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.

Who is behind this study?

The study sponsor is Boehringer Ingelheim.

Did this study involve medication?

Yes. The study involved medication, including Iclepertin and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies